Logo image of SCNX

SCIENTURE HOLDINGS INC (SCNX) Stock Fundamental Analysis

USA - NASDAQ:SCNX - US80880X1046 - Common Stock

0.8548 USD
-0.04 (-4.28%)
Last: 9/22/2025, 9:54:05 AM
Fundamental Rating

1

SCNX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. SCNX has a bad profitability rating. Also its financial health evaluation is rather negative. SCNX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCNX had negative earnings in the past year.
SCNX had a negative operating cash flow in the past year.
SCNX had negative earnings in 4 of the past 5 years.
SCNX had a negative operating cash flow in each of the past 5 years.
SCNX Yearly Net Income VS EBIT VS OCF VS FCFSCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

The Return On Assets of SCNX (-19.30%) is comparable to the rest of the industry.
SCNX's Return On Equity of -25.86% is in line compared to the rest of the industry. SCNX outperforms 57.14% of its industry peers.
Industry RankSector Rank
ROA -19.3%
ROE -25.86%
ROIC N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
SCNX Yearly ROA, ROE, ROICSCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

Looking at the Gross Margin, with a value of 5.77%, SCNX is doing worse than 85.71% of the companies in the same industry.
In the last couple of years the Gross Margin of SCNX has declined.
SCNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
SCNX Yearly Profit, Operating, Gross MarginsSCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

SCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCNX has more shares outstanding
Compared to 5 years ago, SCNX has more shares outstanding
SCNX has a better debt/assets ratio than last year.
SCNX Yearly Shares OutstandingSCNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
SCNX Yearly Total Debt VS Total AssetsSCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.83, we must say that SCNX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SCNX (-0.83) is worse than 60.00% of its industry peers.
SCNX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SCNX's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. SCNX outperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -0.83
ROIC/WACCN/A
WACC9.13%
SCNX Yearly LT Debt VS Equity VS FCFSCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.11 indicates that SCNX may have some problems paying its short term obligations.
SCNX has a worse Current ratio (0.11) than 91.43% of its industry peers.
SCNX has a Quick Ratio of 0.11. This is a bad value and indicates that SCNX is not financially healthy enough and could expect problems in meeting its short term obligations.
SCNX's Quick ratio of 0.11 is on the low side compared to the rest of the industry. SCNX is outperformed by 91.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
SCNX Yearly Current Assets VS Current LiabilitesSCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

SCNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.26%.
Looking at the last year, SCNX shows a very negative growth in Revenue. The Revenue has decreased by -97.10% in the last year.
SCNX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -55.05% yearly.
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNX Yearly Revenue VS EstimatesSCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SCNX Yearly EPS VS EstimatesSCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCNX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCNX Price Earnings VS Forward Price EarningsSCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNX Per share dataSCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCIENTURE HOLDINGS INC

NASDAQ:SCNX (9/22/2025, 9:54:05 AM)

0.8548

-0.04 (-4.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-04 2025-11-04
Inst Owners1.27%
Inst Owner Change-3.56%
Ins Owners17.82%
Ins Owner ChangeN/A
Market Cap17.74M
Analysts82.86
Price TargetN/A
Short Float %0.84%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend3.08
Dividend Growth(5Y)N/A
DP-10.87%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 138.25
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.01
BVpS3.75
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.3%
ROE -25.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.77%
FCFM N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.48%
Cap/Sales 9.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -0.83
F-Score2
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5015.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26676.4%
OCF growth 3YN/A
OCF growth 5YN/A